image

Vaccines Market Report Scope & Overview :

Vaccines Market was valued at USD 67.51 Bn in 2022 and is expected to reach USD 151 Bn by 2030 and grow at a CAGR of 10.6% during the forecasted period 2023-2030.

Vaccines are pharmaceuticals created to boost a person's immune system and protect them from particular infectious diseases. They frequently include fragments of the disease-causing bacteria, weakened or inactive versions of the microbe, or a modified form of a toxin the microorganism produces. When a person receives a vaccination, it stimulates their immune system to identify and remember the particular pathogen so that, in the future, if they are exposed to the actual infectious agent, their immune system may promptly react and prevent or lessen the disease. Vaccines have considerably decreased the prevalence of illnesses, impairments, and fatalities globally and have helped stop the spread of numerous diseases. They have been created to treat a variety of infectious diseases, such as diphtheria, tetanus, hepatitis, measles, polio, and influenza.

Vaccines Market Revenue Analysis

Market Dynamics :

Driver : The rising diseases, clinical trials where the need of vaccines is upheld.

The main goal of vaccinations is to stop the spread of infectious diseases and shield people from getting potentially life-threatening illnesses. Vaccines are made to encourage the immune system to identify and respond to particular infections effectively, lowering the chance of infection and its associated problems. By lowering the overall prevalence of diseases within communities, vaccination significantly contributes to public health. The spread of infectious illnesses is greatly slowed down when a large section of the population is immunized, a phenomenon known as "herd immunity" or "community immunity," even among people who are unvaccinated or who are unable to obtain vaccines for medical reasons.

Restrain : The stringent rules and regulations for the approval purpose.

Opportunity : The rising development and the rise in the R&D related to the drug innovation.

Vaccines are essential to maintaining the safety of the world's health, particularly in the face of pandemics and newly emerging infectious illnesses. Rapid vaccine creation, distribution, and use can help stop outbreaks, stop diseases from crossing international borders, and lessen their worldwide impact. A current illustration of the significance of vaccines in safeguarding populations around the world is the COVID-19 pandemic. Research and Innovation: The creation of vaccines encourages continued study of immunology and infectious illness. Scientists consistently try to produce new vaccines, enhance existing ones, and investigate innovative               

Challenge : The lack of access in the emerging countries as the supply and demand factor can cause barrier for the countries with poor infrastructure.

Impact of Russia Ukraine War :

Hospitals, clinics, and supply chains are all parts of the healthcare infrastructure that can be damaged by conflict. This may make it more difficult for people to receive healthcare services in general as well as the administration and distribution of immunizations. Inadequate healthcare systems can cause delays or disruptions in the distribution of vaccines, which could have an impact on vaccination coverage rates. Limited Access to Vaccines: Access to vaccines may be hindered by conflict, particularly in areas that have been directly impacted by the fighting or where infrastructure has been damaged. People may find it challenging to reach vaccination clinics or obtain routine immunization services due to population displacement, travel limitations, and insecurity.

Impact of recession :  

During a recession, governments and healthcare budgets may experience difficulties, which could result in decreased funding for healthcare efforts like vaccination campaigns. This may have an impact on funding for vaccine research and development, vaccine distribution plans, and immunization campaigns. Affordability and Affected Demand: Financial troubles for people and families during a recession can make healthcare services, including vaccines, more expensive. Consumption of non-essential healthcare services, such as those vaccines not covered by conventional immunization programmers, may decline when disposable income declines. This might have an effect on immunization rates.

Market Segmentation

By Type

  • Recombinant

  • Inactivated

  • Live Attenuated

  • Toxoid

By Route of Administration

  • Parenteral

  • Oral

By Disease indication

  • Viral diseases

  • Bacterial Diseases

By Age Group

  • Pediatric

  • Adults

Vaccines Market Segmentation Analysis

Regional Analysis :

North America region will dominate the market because of the significant pharmaceutical businesses and research institutions, the region has strong capacity for developing vaccines. Programs for immunization span a wide range of diseases, from immunizations for children to those for adults. Although vaccination rates are generally high, certain groups continue to express vaccine hesitation.

Europe Is the region with the second highest share as the Vaccination programs vary from nation to nation but often include both advised adult vaccinations and routine kid immunizations. High vaccination rates are found in European nations, yet some regions are facing difficulties due to vaccine reluctance. The coordination of vaccine procurement and distribution efforts is greatly aided by the European Union.

Key players :

The major key players are Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co, Inc, Inovio pharmaceuticals, Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Moderna and others.

GlaxoSmithKline plc-Company Financial Analysis

Company Landscape Analysis

Recent Development :

Pfizer : The approval form FDA  for ABRYSVO vaccine which will be used for the prevention of respiratory Syncytial virus (RSV) in older adults.    

Moderna : The official announcement form the company related to the mRNA-1345 vaccine which has met primary efficacy endpoints in Phase 3 trial.

Bavarian Nordic : The disclosure of the phase 3 clinical trial of VLP Based Chikungunya virus vaccines in adults which will be used for patients who are above 65 years old.

Vaccines Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 67.51 Bn
Market Size by 2030  US$ 151 Bn
CAGR   CAGR of 10.6% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Type (Recombinant, Inactivated, Live Attenuated, Toxoid)
• By Route of Administration (Parenteral, Oral)
• By Disease Indication (Viral diseases, Bacterial Diseases)
• By Age Group (Pediatric, Adults)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co, Inc, Inovio pharmaceuticals, Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Moderna and others
Key Drivers • The rising diseases, clinical trials where the need of vaccines is upheld.
Market Opportunities • The rising development and the rise in the R&D related to the drug innovation.

 

Frequently Asked Questions

Ans : The Vaccines Market was valued at USD 67.51 Bn in 2022 and is expected to reach USD 151 Bn by 2030 and grow at a CAGR of 10.6% during the forecasted period 2023-2030.

Ans: The rising diseases, clinical trials where the need of vaccines is upheld.

Ans : The major key players are Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co, Inc, Inovio pharmaceuticals, Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Moderna and others.

Ans : During a recession, governments and healthcare budgets may experience difficulties, which could result in decreased funding for healthcare efforts like vaccination campaigns.

Ans: Vaccines market is divided into four segments.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Vaccines Market Segmentation, by Type
8.1 Recombinant
8.2 Inactivated
8.3 Live Attenuated
8.4 Toxoid

9. Vaccines Market Segmentation, By Route of Administration
9.1 Parenteral
9.2 Oral

10. Vaccines Market Segmentation, By Disease Indication
10.1 Viral diseases
10.2 Bacterial Diseases

11. Vaccines Market Segmentation, By Age Group
11.1 Pediatric
11.2 Adults

12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Vaccines Market by country
12.2.2North America Vaccines Market by Type
12.2.3 North America Vaccines Market by Route of Administration
12.2.4 North America Vaccines Market by Disease Indication
12.2.5 North America Vaccines Market by Age Group
12.2.6 USA
12.2.6.1 USA Vaccines Market by Type
12.2.6.2 USA Vaccines Market by Route of Administration
12.2.6.3 USA Vaccines Market by Disease Indication
12.2.6.4 USA Vaccines Market by Age Group
12.2.7 Canada
12.2.7.1 Canada Vaccines Market by Type
12.2.7.2 Canada Vaccines Market by Route of Administration
12.2.7.3 Canada Vaccines Market by Disease Indication
12.2.7.4 Canada Vaccines Market by Age Group
12.2.8 Mexico
12.2.8.1 Mexico Vaccines Market by Type
12.2.8.2 Mexico Vaccines Market by Route of Administration
12.2.8.3 Mexico Vaccines Market by Disease Indication
12.2.8.4 Mexico Vaccines Market by Age Group
12.3 Europe
12.3.1 Europe Vaccines Market by country
1.3.3.2 Europe Vaccines Market by Type
12.3.3 Europe Vaccines Market by Route of Administration
12.3.4 Europe Vaccines Market by Disease Indication
12.3.5 Europe Vaccines Market by Age Group
12.3.6 Germany
12.3.6.1 Germany Vaccines Market by Type
12.3.6.2 Germany Vaccines Market by Route of Administration
12.3.6.3 Germany Vaccines Market by Disease Indication
12.3.6.4 Germany Vaccines Market by Age Group
12.3.7 UK
12.3.7.1 UK Vaccines Market by Type
12.3.7.2 UK Vaccines Market by Route of Administration
12.3.7.3 UK Vaccines Market by Disease Indication
12.3.7.4 UK Vaccines Market by Age Group
12.3.8 France
12.3.8.1 France Vaccines Market by Type
12.3.8.2 France Vaccines Market by Route of Administration
12.3.8.3 France Vaccines Market by Disease Indication
12.3.8.4 France Vaccines Market by Age Group
12.3.9 Italy
12.3.9.1 Italy Vaccines Market by Type
12.3.9.2 Italy Vaccines Market by Route of Administration
12.3.9.3 Italy Vaccines Market by Disease Indication
12.3.9.4 Italy Vaccines Market by Age Group
12.3.10 Spain
12.3.10.1 Spain Vaccines Market by Type
12.3.10.2 Spain Vaccines Market by Route of Administration
12.3.10.3 Spain Vaccines Market by Disease Indication
12.3.10.4 Spain Vaccines Market by Age Group
12.3.11 The Netherlands
12.3.11.1 Netherlands Vaccines Market by Type
12.3.11.2 Netherlands Vaccines Market by Route of Administration
12.3.11.3 Netherlands Vaccines Market by Disease Indication
12.3.11.4 Netherlands Vaccines Market by Age Group
12.3.12 Rest of Europe
12.3.12.1 Rest of Europe Vaccines Market by Type
12.3.12.2 Rest of Europe Vaccines Market by Route of Administration
12.3.12.3 Rest of Europe Vaccines Market by Disease Indication
12.3.12.4 Rest of Europe Vaccines Market by Age Group
12.4 Asia-Pacific
12.4.1 Asia Pacific Vaccines Market by country
12.4.2 Asia Pacific Vaccines Market by Type
12.4.2 Asia Pacific Vaccines Market by Route of Administration
12.4.4Asia Pacific Vaccines Market by Disease Indication
12.4.5Asia Pacific Vaccines Market by Age Group
12.4.6 Japan
12.4.6.1 Japan Vaccines Market by Type
12.4.6.2 Japan Vaccines Market by Route of Administration
12.4.6.3 Japan Vaccines Market by Disease Indication
12.4.6.4 Japan Vaccines Market by Age Group
12.4.7 South Korea
12.4.7.1 South Korea Vaccines Market by Type
12.4.7.2 South Korea Vaccines Market by Route of Administration
12.4.7.3 South Korea Vaccines Market by Disease Indication
12.4.7.4 South Korea Vaccines Market by Age Group
12.4.8 China
12.4.8.1 China Vaccines Market by Type
12.4.8.2 China Vaccines Market by Route of Administration
12.4.8.3 China Vaccines Market by Disease Indication
12.4.8.4 China Vaccines Market by Age Group
12.4.9 India
12.4.9.1 India Vaccines Market by Type
12.4.9.2 India Vaccines Market by Route of Administration
12.4.9.3 India Vaccines Market by Disease Indication
12.4.9.4 India Vaccines Market by Age Group
12.4.10 Australia
12.4.10.1 Australia Vaccines Market by Type
12.4.10.2 Australia Vaccines Market by Route of Administration
12.4.10.3 Australia Vaccines Market by Disease Indication
12.4.10.4 Australia Vaccines Market by Age Group
12.4.11 Rest of Asia-Pacific
12.4.11.1 APAC Vaccines Market by Type
12.4.11.2 APAC Vaccines Market by Route of Administration
12.4.11.3 APAC Vaccines Market by Disease Indication
12.4.11.4 APAC Vaccines Market by Age Group
12.5 The Middle East & Africa
12.5.1 The Middle East & Africa Vaccines Market by country
12.5.2 The Middle East & Africa Vaccines Market by Type
12.5.3 The Middle East & Africa Vaccines Market by Route of Administration
12.5.4The Middle East & Africa Vaccines Market by Disease Indication
12.5.5 The Middle East & Africa Vaccines Market by Age Group
12.5.6 Israel
12.5.6.1 Israel Vaccines Market by Type
12.5.6.2 Israel Vaccines Market by Route of Administration
12.5.6.3 Israel Vaccines Market by Disease Indication
12.5.6.4 Israel Vaccines Market by Age Group
12.5.7 UAE
12.5.7.1 UAE Vaccines Market by Type
12.5.7.2 UAE Vaccines Market by Route of Administration
12.5.7.3 UAE Vaccines Market by Disease Indication
12.5.7.4 UAE Vaccines Market by Age Group
12.5.8 South Africa
12.5.8.1 South Africa Vaccines Market by Type
12.5.8.2 South Africa Vaccines Market by Route of Administration
12.5.8.3 South Africa Vaccines Market by Disease Indication
12.5.8.4 South Africa Vaccines Market by Age Group
12.5.9 Rest of Middle East & Africa
12.5.9.1 Rest of Middle East & Asia Vaccines Market by Type
12.5.9.2 Rest of Middle East & Asia Vaccines Market by Route of Administration
12.5.9.3 Rest of Middle East & Asia Vaccines Market Disease Indication
12.5.9.4 Rest of Middle East & Asia Vaccines Market by Age Group
12.6 Latin America
12.6.1 Latin America Vaccines Market by country
12.6.2 Latin America Vaccines Market by Type
12.6.3 Latin America Vaccines Market by Route of Administration
12.6.4 Latin America Vaccines Market by Disease Indication
12.6.5  Latin America Vaccines Market by Age Group
12.6.6 Brazil
12.6.6.1 Brazil Vaccines Market by Type
12.6.6.2 Brazil Africa Vaccines Market by Route of Administration
12.6.6.3 Brazil Vaccines Market by Disease Indication
12.6.6.4 Brazil Vaccines Market by Age Group
12.6.7 Argentina
12.6.7.1 Argentina Vaccines Market by Type
12.6.7.2 Argentina Vaccines Market by Route of Administration
12.6.7.3 Argentina Vaccines Market by Disease Indication
12.6.7.4 Argentina Vaccines Market by Age Group
12.6.8 Rest of Latin America
12.6.8.1 Rest of Latin America Vaccines Market by Type
12.6.8.2 Rest of Latin America Vaccines Market by Route of Administration
12.6.8.3 Rest of Latin America Vaccines Market by Disease Indication
12.6.8.4 Rest of Latin America Vaccines Market by Age Group

13 Company profile
13.1 Sanofi
13.1.1 Market Overview
13.1.2 Financials
13.1.3 Treatment/Services/Offerings
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Pfizer
13.2.1 Market Overview
13.2.2 Financials
13.2.3 Treatment/Services/Offerings
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 GlaxoSmithKline plc
13.3.1 Market Overview
13.3.2 Financials
13.3.3 Treatment/Services/Offerings
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Merck & Co
13.4.1 Market Overview
13.4.2 Financials
13.4.2 Treatment/Services/Offerings
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Inovio pharmaceuticals
13.5.1 Market Overview
13.5.2 Financials
13.5.3 Treatment/Services/Offerings
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Bavarian Nordic
13.6.1 Market Overview
13.6.2 Financials
13.6.3 Treatment/Services/Offerings
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Mitsubishi Tanabe Pharma Corporation
13.7.1 Market Overview
13.7.2 Financials
13.7.3 Treatment/Services/Offerings
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Novartis AG
13.8.1 Market Overview
13.8.2 Financials
13.8.3 Treatment/Services/Offerings
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Moderna
13.9.1 Market Overview
13.9.2 Financials
13.9.3 Treatment/Services/Offerings
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Others
13.10.1 Market Overview
13.10.2 Financials
13.10.3 Treatment/Services/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View

14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share analysis
14.2 Recent Developments

15. USE Cases and Best Practices

16. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone